Cumberland Pharmaceuticals Inc. (CPIX) EPS Estimated At $-0.08

July 14, 2018 - By Adrian Erickson

Investors sentiment decreased to 0.69 in 2018 Q1. Its down 0.17, from 0.86 in 2017Q4. It dived, as 4 investors sold Cumberland Pharmaceuticals Inc. shares while 9 reduced holdings. 1 funds opened positions while 8 raised stakes. 4.09 million shares or 0.64% less from 4.12 million shares in 2017Q4 were reported.
Blackrock reported 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). California Public Employees Retirement Systems accumulated 53,800 shares. Tower Research Limited Company (Trc) holds 0% or 431 shares in its portfolio. Sei has invested 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Oakworth Inc reported 0% stake. Morgan Stanley owns 20,415 shares for 0% of their portfolio. Bankshares Of New York Mellon Corporation invested in 24,838 shares or 0% of the stock. Cambridge Investment Research has 10,000 shares. Spark Invest Mngmt invested in 10,800 shares or 0% of the stock. The New York-based Renaissance Techs Limited Co has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Acadian Asset Mngmt Lc stated it has 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Dimensional Fund Advsr L P reported 883,085 shares. Geode Capital Management Ltd Llc reported 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Bard owns 83,215 shares or 0.28% of their US portfolio. Prudential Fincl Incorporated invested in 0% or 20,600 shares.

Since March 19, 2018, it had 2 insider purchases, and 0 sales for $4,464 activity.

Analysts expect Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) to report $-0.08 EPS on August, 14.They anticipate $0.01 EPS change or 14.29 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Cumberland Pharmaceuticals Inc.’s analysts see -27.27 % EPS growth. The stock increased 1.46% or $0.09 during the last trading session, reaching $6.24. About 1,133 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has declined 14.79% since July 14, 2017 and is downtrending. It has underperformed by 27.36% the S&P500.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Ratings Coverage

Among 2 analysts covering Cumberland (NASDAQ:CPIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cumberland had 2 analyst reports since April 17, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, April 17 by FBR Capital.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. The company has market cap of $98.04 million. It marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. It currently has negative earnings. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.